Question 1

What are the main differences between CS-3150 and olmesartan medoxomil?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my specific health factors affect my eligibility for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

Question 3

What potential side effects should I be aware of with these medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the trial and what will that involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there other treatment options available that I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

Question 6

What kind of monitoring will be done during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension clinical trial (NCT02848170). Contact the study team or your healthcare provider for specific answers.

What this study is about